You are here
ASCO 2017 Highlights
A series of congress highlights and recommended abstracts from the resource centre editorial board.
Professor Florian Lordick and Dr Elizabeth Smyth make a selection of their recommended abstracts in Upper GI from ASCO 2017. These include abstracts with the latest trial date including:
KEYNOTE-059 cohort 1 and KEYNOTE-059 cohort 2 trials (Pembrolizumab), the CheckMate 032 study (Nivolumab / ipilimumab) and FLOT4 (5-FU, Leucovorin, Oxaliplatin und Docetaxel) which can now be regarded as a new standard regimen in patients with locally advanced gastric cancer and adenocarcinoma of the oesophago-gastric junction. View the abstracts and further editorial insight here:
Dr Chiara Cremolini makes a selection of her recommended abstracts in colorectal cancer from ASCO 2017 including editorial insight on two translational issues that emerged at the meeting - The potential interest of the quantitative and qualitative evaluation of cfDNA in liquid biopsy and the Consensus Molecular Subgroups (CMS) classification of colorectal cancer. View the abstracts and further editorial insight here:
Professor Michel Ducreux makes a selection of his recommended abstracts in colorectal cancer from ASCO 2017. Prof Ducreux gives insight on the latest significant clinical trial data including: FOXFIRE (5-Fluorouracil, OXaliplatin and Folinic acid +/- Interventional Radio-Embolisation), FRESCO (Fruquintinib Efficacy) and the IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. View the abstracts and further editorial insight here: